177Lu-EB-PSMA-617 在转移性去势抵抗性前列腺癌患者的首次人体研究
这项首次人体研究纳入9例mCRPC患者,4例接受0.80-1.1 GBq的177Lu-EB-PSMA-617,5例接受1.30-1.42 GBq的177Lu-PSMA-617,比较安全性与剂量学。结果显示177Lu-EB-PSMA-617在骨转移灶的累积放射性约为177Lu-PSMA-617的3.02倍,且一个月内68Ga-PSMA-617摄取显著下降(SUV变化-32.43±0.14% vs 0.21±0.37%,P=0.002)。红骨髓和肾脏吸收剂量更高,但在所给低剂量下耐受良好。
要点
- 177Lu-EB-PSMA-617在骨转移灶的累积放射性约为177Lu-PSMA-617的3.02倍。
- 177Lu-EB-PSMA-617组一个月内68Ga-PSMA-617摄取显著下降,SUV变化-32.43±0.14% vs 0.21±0.37%,P=0.002。
- 红骨髓和肾脏吸收剂量更高,但在所给低剂量下耐受良好。
核心结论
- 这项首次人体研究显示177Lu-EB-PSMA-617在mCRPC中具有更高的累积,低成像剂量似乎对高68Ga-PSMA-617摄取的肿瘤有治疗作用。
- 177Lu-EB-PSMA-617在肾脏和红骨髓中摄取升高,但在所给低剂量下耐受良好。
- 需要进一步研究增加剂量和给药频率。
研究设计与样本
- 这项转化研究纳入9例mCRPC患者,4例接受静脉注射0.80-1.1 GBq(21.5-30 mCi)177Lu-EB-PSMA-617,5例接受静脉注射1.30-1.42 GBq(35-38.4 mCi)177Lu-PSMA-617。
- 177Lu-EB-PSMA-617组在2、24、72、120和168小时行系列全身平面和SPECT/CT显像,177Lu-PSMA-617组在0.5、2、24、48和72小时行相同显像。
- 所有患者在治疗前和治疗后一个月接受68Ga-PSMA-617 PET/CT评估,并比较两组剂量学。
主要发现
- 从两组中选取基线SUVmax在10.0-15.0范围内可比的骨转移肿瘤进行比较,177Lu-EB-PSMA-617的累积放射性约为177Lu-PSMA-617的3.02倍。
- 177Lu-EB-PSMA-617治疗组显像显示一个月内68Ga-PSMA-617摄取显著下降,而177Lu-PSMA-617组未观察到(SUV变化:-32.43±0.14% vs 0.21±0.37%;P=0.002)。
- 177Lu-EB-PSMA-617的红骨髓和肾脏吸收剂量高于177Lu-PSMA-617(红骨髓:0.0547±0.0062 vs 0.0084±0.0057 mSv/MBq,P<0.01;肾脏:2.39±0.69 vs 0.39±0.06 mSv/MBq,P<0.01)。
临床怎么用
- 作者认为低成像剂量的177Lu-EB-PSMA-617似乎对高68Ga-PSMA-617摄取的肿瘤有治疗作用。
- 作者指出需要进一步研究增加剂量和给药频率。
局限性
- 需要进一步研究增加剂量和给药频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This translational study is designed to assess the safety, dosimetry and therapeutic response to a single, low-dose of 177Lu-EB-PSMA-617 in comparison to 177Lu-PSMA-617 in patients with mCRPC. METHODS: Following institutional review board approval and informed consent, nine patients with mCRPC were recruited. Four patients accepted intravenous injection of 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then underwent serial whole-body planar and SPECT/CT imaging at 2, 24, 72, 120 and 168 h. The other five patients accepted intravenous injection of 1.30-1.42 GBq (35-38.4 mCi) 177Lu-PSMA-617, then underwent the same imaging procedures at 0.5, 2, 24, 48, and 72 h. All patients were evaluated by 68Ga-PSMA-617 PET/CT before and one month after the treatment. Dosimetry evaluation was compared in both patient groups. RESULTS: When the bone metastasis tumors with comparable baseline SUVmax in the range of 10.0-15.0 were selected from the two groups for comparison, the accumulated radioactivity of 177Lu-EB-PSMA-617 was about 3.02-fold higher than that of 177Lu-PSMA-617. Imaging dose of 177Lu-EB-PSMA-617 treatment showed significant decrease of 68Ga-PSMA-617 uptake within a month, which was not observed in patients imaged with 177Lu-PSMA-617 (SUV change: -32.43 ± 0.14% vs. 0.21 ± 0.37%; P = 0.002). 177Lu-EB-PSMA-617 also had higher absorbed doses in the red bone marrow and kidneys than 177Lu-PSMA-617 (0.0547 ± 0.0062 vs. 0.0084 ± 0.0057 mSv/MBq for red bone marrow, P < 0.01; 2.39 ± 0.69 vs. 0.39 ± 0.06 mSv/MBq for kidneys, P < 0.01). CONCLUSION: This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EB-PSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted.
引用
- Zang J, Fan X, Wang H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30090965. doi:10.1007/s00259-018-4096-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。